Why Is INSMED INC (INSM) Stock Up Today?

INSM stock surged 33.86% to $132.55 on Thursday driven by a combination of strong second-quarter results and raised revenue guidance for its flagship product, Brinsupri. The company reported 296% revenue growth and lifted its sales forecast for the year, with peak sales expectations now exceeding $14 billion. Jefferies also raised its price target for INSM to $175 from $160, adding further momentum to the rally.

What Happened

Insmed delivered a standout Q2 2026 with revenue of $425.5 million, a 115.1% increase year over year. The company attributed the performance to robust sales of Brinsupri (brensocatib), which showed significant growth in its respiratory therapy segment. In response, Insmed raised its full-year Brinsupri revenue guidance to a range of $1.25 billion to $1.40 billion and increased peak sales expectations for its three lead programs to more than $14 billion. Jefferies followed the news by upgrading its price target, reinforcing the positive outlook for the stock. The earnings call transcript and multiple reports highlighted the company’s progress in its pipeline and therapeutic development.

What The Data Shows

Over the past eight trading sessions, INSM has gained 25.5%, rising from $104.13 to $130.71. The recent move has brought the stock closer to its 52-week high of $212.75. Unusual options activity over the past 36 hours included five notable prints, with call premiums totaling $2.2 million and put premiums at $1.1 million. The largest single options trade was worth $1.4 million. Insider transactions over the last 90 days totaled 18 sales, amounting to $16.4 million, with no insider purchases reported.

What To Watch

Insmed’s next key event will be its Q2 2026 earnings call on August 6, 2026. Investors will be watching for further details on Brinsupri’s performance and pipeline developments. Coverage breadth is also a factor, with 12 stories from seven sources published in the last 36 hours.